Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030
주사용 약물전달 기기 시장 규모는 2025년 2,563억 달러에서 2030년 3,737억 달러에 달할 것으로 예상되며, 예측 기간 동안 7.8%의 CAGR을 기록할 것으로 예상됩니다.
주사용 약물전달 제제 시장은 2025년 4,340억 달러에서 2030년 6,611억 달러에 달할 것으로 예상되며, 예측 기간 동안 8.8%의 CAGR을 기록할 것으로 예상됩니다.
| 조사 범위 |
| 조사 대상 연도 |
2024-2030년 |
| 기준 연도 |
2024년 |
| 예측 기간 |
2024-2030년 |
| 검토 단위 |
금액(10억 달러) |
| 부문별 |
제품별, 제형 포장별, 치료 용도별, 사용 패턴별, 투여 부위별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
주사용 약물전달 시장은 환자 중심의 표적화된 최소침습적 치료 솔루션에 대한 수요 증가로 인해 빠르게 변화하고 있습니다. 이 시장의 주요 트렌드는 자동 주사기, 펜형 주사기, 웨어러블 주사기 등 자가 주사 기술로의 전환입니다. 이러한 발전은 환자의 순응도를 높이고, 당뇨병, 류마티스 관절염, 다발성 경화증과 같은 만성질환을 관리하는 데 특히 중요한 재택 치료를 용이하게 해줍니다.
기술의 발전은 점점 더 많은 시장을 형성하고 있습니다. 연결 기능, 용량 추적 및 알림 시스템을 갖춘 스마트 주사기는 디지털 헬스케어의 광범위한 추세를 반영하여 점점 더 널리 보급되고 있습니다. 또한, 마이크로니들 및 무침 주사기의 통합은 특히 소아 및 노년층의 경우, 기존 주사기 사용으로 인한 통증과 불안을 완화하는 데 도움이 되고 있습니다.
제약 업계에서는 장기지속형 제제, 생물학적 제제, 바이오시밀러에 대한 관심이 높아지면서 정확한 전달 시스템이 요구되고 있습니다. 이러한 추세는 의약품 개발자와 기기 제조업체와의 긴밀한 협력을 촉진하고 있습니다. 또한, 규제 기관은 복합제를 더 잘 지원하기 위해 프레임워크를 업데이트하고 있으며, 이는 제품 승인 속도를 높이는 데 도움이 되고 있습니다.
2025년부터 2030년까지 주사제 전달 시장 내에서 자가주사 장치 분야가 가장 높은 성장률을 보일 것으로 예상됩니다. 이러한 성장의 원동력은 세계 분산형 의료로의 전환, 만성질환의 유병률 증가, 환자의 자율성에 대한 중요성 증가에 기인합니다. 자가주사기에는 자동주사기, 펜형 주사기, 웨어러블 주사기 등이 있으며, 임상 환경의 필요성을 줄이면서 편의성과 정확성을 제공합니다. 따라서 특히 장기간의 치료에 적합합니다.
미국과 캐나다에서는 자가면역질환 및 대사성 질환 치료에 생물학적 제제의 높은 채택률과 더불어, 유리한 상환 정책 및 헬스케어 분야에서의 디지털 기술 통합이 성장의 원동력이 되고 있습니다. 유럽, 특히 독일, 프랑스, 영국에서는 노인 인구의 증가와 만성질환 관리 프로그램 구축으로 인해 수요가 크게 증가하고 있습니다. 아시아태평양에서는 일본, 중국, 인도 등의 국가들이 의료 접근성 개선, 환자 인식 개선, 바이오시밀러의 가용성 증가로 인해 빠르게 성장하고 있습니다.
스마트 커넥티비티 기능, 용량 메모리, 통증 완화 기술 등의 기술 동향은 기기의 매력을 높이고 있으며, COVID-19 사태로 인해 환자들이 병원을 피하고 집에서 치료받는 것을 선호하면서 셀프 케어의 채택이 가속화되고 있습니다. 제약회사와 의료기기 제조업체와의 협업도 증가하고 있으며, 맞춤형 주사 요법 솔루션이 가능해지고 있습니다. 전반적으로 이 부문의 급격한 성장은 임상적 요구, 환자 선호도, 기술 발전의 강력한 조합을 반영합니다.
앰플 부문은 2024년 주사용 약물전달 시장 내 시장 점유율에 크게 기여했습니다. 앰플은 우수한 무균성, 저렴한 가격, 다양한 약물 제형에 대한 적응성으로 인해 이 시장에서 가장 빠르게 성장하는 포장 분야입니다. 일반적으로 유리 또는 플라스틱 앰플은 오염의 위험 없이 1회용 주사제를 보관하는 데 이상적이며, 급성기 의료 및 병원 환경에서 매우 선호되고 있습니다.
인도, 브라질, 베트남과 같은 신흥 경제 국가에서 앰플은 비용 효율성이 뛰어나 정부의 예방접종 및 예방접종 프로그램에 널리 사용되고 있습니다. 또한, 다양한 생물학적 제제 및 저분자 의약품과의 호환성이 종양학, 항감염제, 호르몬 요법 등의 치료 분야에서 채택을 촉진하고 있습니다.
아시아태평양은 인구통계학적, 경제적, 의료적 요인이 복합적으로 작용하여 주사용 약물전달 시장에서 가장 빠르게 성장하는 지역으로 부상하고 있습니다. 중국이나 인도와 같은 대국에서는 만성질환, 특히 당뇨병과 암의 유병률이 증가하면서 고급 주사 요법에 대한 수요가 증가하고 있습니다. 또한, 생물학적 제제에 대한 접근성이 확대됨에 따라 자동주사기나 펜형 주사기와 같이 사용하기 편리한 기기에 대한 수요가 증가하고 있습니다.
중국에서는 정부의 지원 정책, R&D 투자 증가, 생명공학 부문의 번영이 혁신적인 약물전달 시스템의 채택을 촉진하고 있습니다. 한편, 인도에서도 제네릭 의약품 시장의 성장에 힘입어 자가주사기와 바이오시밀러가 크게 성장하고 있습니다. 또한, 베트남, 태국 등 동남아시아 국가들의 의료 인프라가 개선되고 전문 의료에 대한 접근성이 향상되면서 이 지역의 수요가 증가하고 있습니다.
도시화, 가처분 소득의 증가, 고령화로 인해 환자와 의료 서비스 제공자가 편리한 재택 치료 옵션을 찾는 추세에 박차를 가하고 있습니다. 또한, 현지의 제조 능력과 비용 효율적인 생산은 전 세계 제약사 및 의료기기 제조업체의 제휴를 유치하고 있습니다.
본 보고서는 주사용 약물전달 시장을 제품, 치료 용도, 제형, 포장, 사용 패턴, 투여 부위, 최종사용자, 지역별로 조사하였습니다. 또한 시장 성장에 영향을 미치는 요인(시장 촉진요인 및 과제)에 대해서도 조사하고 있습니다. 시장에서의 기회와 과제를 분석하고, 시장 리더의 경쟁 상황에 대한 자세한 정보를 제공합니다. 또한, 개별 성장 동향과 관련하여 마이크로 시장을 분석하고, 주요 6개 지역과 각 국가별 시장 부문의 수익을 예측합니다.
이 보고서는 기존 기업과 신규 또는 소규모 기업 모두 시장 동향을 이해하고 더 큰 시장 점유율을 확보하는 데 도움이 될 것입니다. 본 보고서를 구매한 기업은 다음 5가지 전략 중 하나 이상을 활용할 수 있습니다.
목차
제1장 소개
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
- 시장 역학
- 업계 동향
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 밸류체인 분석
- 공급망 분석
- 생태계 분석
- 투자와 자금 조달 시나리오
- 기술 분석
- 특허 분석
- 무역 분석
- 2025-2026년의 주요 회의와 이벤트
- 사례 연구 분석
- 규제 상황
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- 파이프라인 분석
- 상환 분석
- 미충족 수요/최종사용자 기대
- 주사용 약물전달 시장에 대한 AI/생성형 AI의 영향
- 2025년 미국 관세의 영향
제6장 주사용 약물전달 시장, 제품별
제7장 주사용 약물전달 시장, 제형 포장별
제8장 주사용 약물전달 시장, 치료 용도별
- 소개
- 자가면역질환
- 호르몬장애
- 비만
- 암
- 감염증
- 희귀질환
- 기타
제9장 주사용 약물전달 시장, 사용 패턴별
제10장 주사용 약물전달 시장, 투여 부위별
- 소개
- 경피 투여
- 순환기계/근골격계에 기반한 투여
- 장기 기반 투여
- 중추신경계에 기반한 투여
제11장 주사용 약물전달 시장, 최종사용자별
- 소개
- 병원과 클리닉
- 재택 케어
- 장기간병 환경
- 요양시설
- 기타
제12장 주사용 약물전달 시장, 지역별
- 소개
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 스페인
- 이탈리아
- 네덜란드
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 태국
- 베트남
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
- 중동 및 아프리카의 거시경제 전망
- GCC 국가
- 기타
제13장 경쟁 구도
- 개요
- 주요 진출 기업 전략/강점
- 매출 분석, 2020-2024년
- 시장 점유율 분석, 2024년
- 브랜드/제품 비교
- 주요 기업 연구개발비
- 기업 평가와 재무 지표
- 주사용 약물전달 기기 시장 : 기업 평가 매트릭스(주요 기업), 2024년
- 주사용 약물전달 기기 시장 : 기업 평가 매트릭스(스타트업/중소기업), 2024년
- 주사용 약물전달 제제 시장 : 기업 평가 매트릭스(주요 기업), 2024년
- 주사용 약물전달 제제 시장 : 기업 평가 매트릭스(스타트업/중소기업), 2023년
- 경쟁 시나리오
제14장 기업 개요 : 주사용 약물전달 기기 제조업체
- 주요 진출 기업
- CARDINAL HEALTH
- BD
- B. BRAUN SE
- BAXTER
- TERUMO CORPORATION
- PHILLIPS-MEDSIZE CORPORATION(MOLEX)
- NIPRO
- ICU MEDICAL, INC.
- WEST PHARMACEUTICAL SERVICES, INC.
- GERRESHEIMER AG
- STEVANATO
- SCHOTT PHARMA
- MEDMIX
- SOLM
- YPSOMED
- 기타 기업
- OWEN MUMFORD
- HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
- POLYMEDICURE
- UNION MEDICO INC.
- SHL MEDICAL
- ELCAM MEDICAL
제15장 기업 개요 : 주사용 약물전달 제제 제조업체
- 주요 진출 기업
- JOHNSON & JOHNSON SERVICES, INC.
- F. HOFFMANN-LA ROCHE LTD
- PFIZER INC.
- MERCK & CO., INC.
- NOVARTIS AG
- BAYER AG
- ASTRAZENECA
- TAKEDA PHARMACEUTICAL COMPANY LIMITED.
- ELI LILLY AND COMPANY
- AMGEN INC.
- NOVO NORDISK A/S
- REGENERON PHARMACEUTICALS INC.
- FRESENIUS KABI AG
- UCB S.A.
- BIO-THERA SOLUTIONS, LTD.
- 기타 기업
- SAGENT
- VALNEVA SE
- XERIS PHARMACEUTICALS, INC.
- PHARMAESSENTIA CORPORATION
- HERON THERAPEUTICS, INC.
제16장 부록
ksm
The injectable drug delivery devices market is projected to reach USD 373.7 billion by 2030 from USD 256.3 billion in 2025, at a CAGR of 7.8% during the forecast period. The injectable drug delivery formulations market is projected to reach USD 661.1 billion by 2030 from USD 434.0 billion in 2025, at a CAGR of 8.8% during the forecast period.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | By Product, Therapeutic Application, Therapy Area, Formulation Packaging, Formulation Packaging, Usage Pattern, Site of Administration, End User, Region
|
| Regions covered | North America, Europe, APAC, LATAM, MEA |
The injectable drug delivery market is experiencing rapid transformation due to the increasing demand for patient-centric, targeted, and minimally invasive treatment solutions. A significant trend in this market is the shift toward self-injection technologies, which include autoinjectors, pen injectors, and wearable injectors. These advancements enhance patient compliance and facilitate at-home care, which is especially important for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis.
Technological advancements are increasingly shaping the market. Smart injectors equipped with connectivity features, dose tracking, and reminder systems are becoming more popular, reflecting the broader trend toward digital healthcare. Furthermore, the integration of microneedles and needle-free injectors is helping to reduce the pain and anxiety often associated with traditional syringes, particularly for pediatric and geriatric populations.
The pharmaceutical industry increasingly focuses on long-acting formulations, biologics, and biosimilars, requiring precise delivery systems. This trend is fostering closer collaboration between drug developers and device manufacturers. Additionally, regulatory bodies are updating their frameworks to better support combination products, which is helping to accelerate product approvals.
"By device, the self-injection devices segment is projected to grow at the highest CAGR during the forecast period."
From 2025 to 2030, the self-injection devices segment is expected to grow at the highest rate within the injectable drug delivery market. This growth is driven by a global shift toward decentralized care, an increase in the prevalence of chronic diseases, and a growing emphasis on patient autonomy. Self-injection devices, which include autoinjectors, pen injectors, and wearable injectors, provide convenience and precision while reducing the need for clinical settings. This makes them particularly suitable for long-term therapies.
In the US and Canada, growth is driven by a high adoption rate of biologics for treating autoimmune and metabolic disorders, along with favorable reimbursement policies and the integration of digital technology in healthcare. Demand has increased significantly in Europe, particularly Germany, France, and the UK, due to the expanding geriatric population and well-structured chronic disease management programs. In the Asia Pacific region, countries such as Japan, China, and India are experiencing rapid growth due to improved healthcare access, increased patient awareness, and a rise in the availability of biosimilars.
Technological trends such as smart connectivity features, dose memory, and pain-reduction technologies make devices more appealing. The COVID-19 pandemic has also accelerated the adoption of self-care, as patients tend to avoid hospitals and prefer administering treatments at home. Collaborations between pharmaceutical companies and device manufacturers are increasing, allowing for customized solutions for injectable therapies. Overall, the rapid growth of this segment reflects a strong combination of clinical needs, patient preferences, and technological advancements.
"By formulation packaging, the ampoules segment accounted for the largest market share in 2024."
The ampoules segment was the leading contributor to market share within the injectable drug delivery market in 2024. Ampoules are the fastest-growing packaging segment in this market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings.
In developing economies like India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs. Additionally, their compatibility with various biologics and small-molecule drugs further facilitates adoption across therapeutic areas such as oncology, anti-infectives, and hormonal therapies.
"The Asia Pacific (APAC) region is expected to witness the highest growth rate during the forecast period."
The Asia Pacific region is becoming the fastest-growing area in the injectable drug delivery market, driven by a combination of demographic, economic, and healthcare factors. The increasing prevalence of chronic diseases, particularly diabetes and cancer, in large countries like China and India, is creating a greater demand for advanced injectable therapies. Additionally, as access to biologics expands, there is an increased need for user-friendly devices, such as autoinjectors and pen injectors.
In China, supportive government policies, increasing investment in research and development, and a thriving biotechnology sector are driving the adoption of innovative drug delivery systems. Meanwhile, India, benefiting from a growing generics market, is also seeing significant growth in self-injection devices and biosimilars. Additionally, Southeast Asian countries like Vietnam and Thailand are enhancing their healthcare infrastructure and improving access to specialty care, which is boosting regional demand.
Urbanization, increasing disposable incomes, and a growing aging population contribute to the trend as patients and providers seek convenient, home-based treatment options. Additionally, regional manufacturing capabilities and cost-effective production attract partnerships from global pharmaceutical and device firms.
Breakdown of supply-side primary interviews: * By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) * By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)
Breakdown of demand-side primary interviews: * By Company Type: Hospitals (60%), Ambulatory Surgical Centers (25%), and Home Care Settings (15%) * By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)
Research Coverage
This report studies the injectable drug delivery market based on product, therapeutic application, formulation, packaging, usage pattern, site of administration, end user, and region. The report also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries.
Reasons to Buy the Report
The report can assist both established companies and new or smaller firms understand the market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.
This report provides insights into the following points:
- Analysis of key drivers (increasing chronic diseases, increasing biologics, and technological advancements), restraints (infections associated with needle-stick injuries), challenges (other methods of injectable drug delivery available in the market), and opportunities (increasing demand for generic medicines and biosimilars) influencing the growth of injectable drug delivery market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the injectable drug delivery market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of injectable drug delivery procedures across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the injectable drug delivery market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the injectable drug delivery market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS SEGMENTATION
- 1.3.2 REGIONAL SEGMENTATION
- 1.3.3 YEARS CONSIDERED
- 1.3.4 INCLUSIONS AND EXCLUSIONS
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Primary sources
- 2.1.2.2 Key data from primary sources
- 2.1.2.3 Breakdown of primaries
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
- 2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
- 2.2.3 APPROACH 3: TOP-DOWN APPROACH
- 2.2.4 APPROACH 4: BOTTOM-UP APPROACH
- 2.2.5 APPROACH 4: PRIMARY INTERVIEWS
- 2.2.6 APPROACH 5: DEMAND-SIDE APPROACH
- 2.2.7 APPROACH 6: VOLUME DATA ANALYSIS
- 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
- 2.4 MARKET SHARE ASSESSMENT
- 2.5 RESEARCH ASSUMPTIONS
- 2.5.1 STUDY ASSUMPTIONS
- 2.5.2 GROWTH RATE ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW
- 4.2 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET OVERVIEW
- 4.3 INJECTABLE DRUG DELIVERY MARKET: REGIONAL MIX
- 4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
- 4.5 INJECTABLE DRUG DELIVERY MARKET: DEVELOPING VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
- 5.1 MARKET DYNAMICS
- 5.1.1 DRIVERS
- 5.1.1.1 Growing demand for self-injection devices
- 5.1.1.2 Advancements in drug delivery technologies
- 5.1.1.3 Rising prevalence of chronic diseases
- 5.1.1.4 Growing adoption of biologics and biosimilars
- 5.1.2 RESTRAINTS
- 5.1.2.1 Infections associated with needlestick injuries
- 5.1.2.2 Stringent government regulations
- 5.1.3 OPPORTUNITIES
- 5.1.3.1 Development of novel drug delivery systems
- 5.1.3.2 Growing preference for home-based care devices
- 5.1.3.3 Growth opportunities in emerging economies
- 5.1.4 CHALLENGES
- 5.1.4.1 Alternative methods of drug delivery
- 5.1.4.2 Complexities in developing wearable drug delivery systems
- 5.2 INDUSTRY TRENDS
- 5.2.1 REUSABLE DRUG DELIVERY DEVICES
- 5.2.2 PREFILLED BIOLOGICS
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
- 5.4.1.1 Average selling price trend of key players, by device type
- 5.4.1.2 Average selling price trend of key players, by pen injectors
- 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
- 5.4.2.1 Average selling price trend of pen injectors, by region
- 5.4.2.2 Average selling price trend of needle-free injectors, by region
- 5.4.2.3 Average selling price trend of autoinjectors, by region
- 5.4.2.4 Average selling price trend of wearable injectors, by region
- 5.5 VALUE CHAIN ANALYSIS
- 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
- 5.5.2 RAW MATERIAL PROCUREMENT
- 5.5.3 MANUFACTURING
- 5.5.4 MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
- 5.9.1.1 Autoinjectors and smart injection devices
- 5.9.1.2 Needle-free injection systems and microneedle patches
- 5.9.1.3 Wearable injectors for high-volume delivery
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
- 5.9.2.1 Nanotechnology
- 5.9.2.2 Biodegradable polymers
- 5.9.3 ADJACENT TECHNOLOGIES
- 5.9.3.1 Artificial intelligence and digital therapeutics
- 5.9.3.2 Alternative routes of administration
- 5.10 PATENT ANALYSIS
- 5.10.1 PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY
- 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.11 TRADE ANALYSIS
- 5.11.1 TRADE DATA FOR HS CODE 901890
- 5.11.1.1 Import data
- 5.11.1.2 Export data
- 5.11.2 TRADE DATA FOR HS CODE 90183100
- 5.11.2.1 Import data
- 5.11.2.2 Export data
- 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.13 CASE STUDY ANALYSIS
- 5.14 REGULATORY LANDSCAPE
- 5.14.1 REGULATORY ANALYSIS
- 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.15 PORTER'S FIVE FORCES ANALYSIS
- 5.15.1 BARGAINING POWER OF SUPPLIERS
- 5.15.2 BARGAINING POWER OF BUYERS
- 5.15.3 THREAT OF NEW ENTRANTS
- 5.15.4 THREAT OF SUBSTITUTES
- 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.16.1 KEY STAKEHOLDERS
- 5.16.2 BUYING CRITERIA
- 5.16.2.1 Buying criteria for injectable drug delivery devices
- 5.16.2.2 Buying criteria for injectable drug delivery devices with formulations
- 5.17 PIPELINE ANALYSIS
- 5.18 REIMBURSEMENT ANALYSIS
- 5.19 UNMET NEEDS/END-USER EXPECTATIONS
- 5.20 IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET
- 5.20.1 INTRODUCTION
- 5.20.2 MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
- 5.20.3 AI USE CASES
- 5.20.4 KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES
- 5.20.5 FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
- 5.21 IMPACT OF 2025 US TARIFF
- 5.21.1 INTRODUCTION
- 5.21.2 KEY TARIFF RATES
- 5.21.3 PRICE IMPACT ANALYSIS
- 5.21.4 IMPACT ON COUNTRY/REGION
- 5.21.4.1 North America
- 5.21.4.2 Asia Pacific
- 5.21.4.3 Europe
- 5.21.4.4 Latin America
- 5.21.5 IMPACT ON END-USE INDUSTRIES
6 INJECTABLE DRUG DELIVERY, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 DEVICES
- 6.2.1 CONVENTIONAL INJECTION DEVICES
- 6.2.1.1 By material
- 6.2.1.1.1 Glass injectable devices
- 6.2.1.1.1.1 Light protection, temperature resistance, and impermeability properties to drive market
- 6.2.1.1.2 Plastic injectable devices
- 6.2.1.1.2.1 Rapid increase in demand for syringes to aid growth
- 6.2.1.2 By product
- 6.2.1.2.1 Fillable syringes
- 6.2.1.2.1.1 Ease of use and variable dosing formulations to boost market
- 6.2.1.2.2 Prefilled syringes
- 6.2.1.2.2.1 Minimal drug waste and low weight & space requirements to propel market
- 6.2.1.3 By usability
- 6.2.1.3.1 Reusable injection devices
- 6.2.1.3.1.1 Cost-effective nature to contribute to growth
- 6.2.1.3.2 Disposable injection devices
- 6.2.1.3.2.1 Growing preference for ready-to-use devices to drive market
- 6.2.2 SELF-INJECTION DEVICES
- 6.2.2.1 Needle-free injectors
- 6.2.2.1.1 By product
- 6.2.2.1.1.1 Fillable needle-free injectors
- 6.2.2.1.1.2 Prefilled needle-free injectors
- 6.2.2.1.2 By technology
- 6.2.2.1.2.1 Jet-based needle-free injectors
- 6.2.2.1.2.2 Spring-based needle-free injectors
- 6.2.2.1.2.3 Laser-powered needle-free injectors
- 6.2.2.1.2.4 Vibration-based needle-free injectors
- 6.2.2.1.3 By usability
- 6.2.2.1.3.1 Reusable needle-free injectors
- 6.2.2.1.3.2 Disposable needle-free injectors
- 6.2.2.2 Autoinjectors
- 6.2.2.2.1 By product
- 6.2.2.2.1.1 Fillable autoinjectors
- 6.2.2.2.1.2 Prefilled autoinjectors
- 6.2.2.2.2 By technology
- 6.2.2.2.2.1 Automated autoinjectors
- 6.2.2.2.2.2 Manual autoinjectors
- 6.2.2.2.3 By design
- 6.2.2.2.3.1 Standardized autoinjectors
- 6.2.2.2.3.2 Customized autoinjectors
- 6.2.2.2.4 By usability
- 6.2.2.2.4.1 Reusable autoinjectors
- 6.2.2.2.4.2 Disposable autoinjectors
- 6.2.2.3 Pen injectors
- 6.2.2.3.1 By product
- 6.2.2.3.1.1 Single-chambered pen injectors
- 6.2.2.3.1.2 Double-chambered pen injectors.
- 6.2.2.3.2 By design
- 6.2.2.3.2.1 Standard pen injectors
- 6.2.2.3.2.2 Customized pen injectors
- 6.2.2.3.3 By usability
- 6.2.2.3.3.1 Reusable pen injectors
- 6.2.2.3.3.2 Disposable pen injectors
- 6.2.2.4 Wearable injectors
- 6.2.2.4.1 Increasing need for safe and convenient injections to accelerate growth
- 6.2.2.5 Other self-injection devices
- 6.3 FORMULATIONS
- 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
- 6.3.1.1 Solutions
- 6.3.1.1.1 High stability and sterility benefits to intensify growth
- 6.3.1.2 Reconstituted/lyophilized formulations
- 6.3.1.2.1 Higher suitability for parenteral administration to aid growth
- 6.3.1.3 Suspensions
- 6.3.1.3.1 Innovations in injectable suspensions for stable and sustained delivery to aid growth
- 6.3.1.4 Emulsions
- 6.3.1.4.1 Advancements in injectable emulsions for controlled and sustained drug delivery to drive market
- 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS
- 6.3.2.1 Colloidal dispersions
- 6.3.2.1.1 Niosomes
- 6.3.2.1.1.1 Low toxicity and economical features to speed up growth.
- 6.3.2.1.2 Liposomes
- 6.3.2.1.2.1 Flexible, biocompatible, and fully biodegradable properties to boost market
- 6.3.2.1.3 Polymeric/mixed micelles
- 6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates to boost market
- 6.3.2.1.4 Nanoparticles
- 6.3.2.1.4.1 Solid-lipid nanoparticles
- 6.3.2.1.4.2 Nanosuspensions
- 6.3.2.1.4.3 Nanoemulsions
- 6.3.2.2 Microparticles
- 6.3.2.2.1 Microspheres
- 6.3.2.2.1.1 Growing focus of major pharmaceutical companies on microsphere drug delivery to drive market
- 6.3.2.2.2 Microcapsules
- 6.3.2.2.2.1 Higher biocompatibility properties to augment growth
- 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS
- 6.3.3.1 Decreased side effects and overall medical cost reduction to advance growth
7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING
- 7.1 INTRODUCTION
- 7.2 AMPOULES
- 7.2.1 EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH
- 7.3 VIALS
- 7.3.1 NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH
- 7.4 CARTRIDGES
- 7.4.1 INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH
- 7.5 BOTTLES
- 7.5.1 RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH
8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION
- 8.1 INTRODUCTION
- 8.2 AUTOIMMUNE DISEASES
- 8.2.1 RHEUMATOID ARTHRITIS
- 8.2.1.1 Increased focus on early-stage diagnosis and treatment to amplify growth
- 8.2.2 MULTIPLE SCLEROSIS
- 8.2.2.1 Increasing target patient pool to contribute to growth
- 8.2.3 CROHN'S DISEASE
- 8.2.3.1 Rising use of liposomes to aid growth
- 8.2.4 PSORIASIS
- 8.2.4.1 Lifestyle changes and high disease prevalence to support growth
- 8.2.5 OTHER AUTOIMMUNE DISEASES
- 8.3 HORMONAL DISORDERS
- 8.3.1 DIABETES
- 8.3.1.1 Growing preference for self-injection devices over traditional syringes to drive market
- 8.3.2 REPRODUCTIVE HEALTH DISEASES
- 8.3.2.1 Lack of healthcare facilities and hygiene practices to aid growth
- 8.3.3 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
- 8.3.3.1 High efficacy and safety of heparin for antithrombotic therapy to aid growth
- 8.3.4 OSTEOPOROSIS
- 8.3.4.1 Increasing number of women with calcium and vitamin D deficiencies to foster growth
- 8.3.5 GROWTH HORMONE DEFICIENCY
- 8.3.5.1 Increased need for daily injections of recombinant human growth hormones to fuel market
- 8.4 OBESITY
- 8.4.1 CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH
- 8.5 CANCER
- 8.5.1 INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH
- 8.6 INFECTIOUS DISEASES
- 8.6.1 GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET
- 8.7 ORPHAN DISEASES
- 8.7.1 FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH
- 8.8 OTHER THERAPEUTIC APPLICATIONS
- 8.8.1 PAIN MANAGEMENT
- 8.8.1.1 Growing focus on treating chronic pain to drive market
- 8.8.2 ALLERGIES
- 8.8.2.1 Increasing prevalence of asthma and eczema to promote growth
- 8.8.3 AESTHETIC TREATMENTS
- 8.8.3.1 Growing popularity of aesthetic procedures to propel market
- 8.8.4 HEPATITIS C
- 8.8.4.1 Need to curb virus spread due to needle reshare to sustain growth
- 8.8.5 HEMOPHILIA
- 8.8.5.1 Increasing need for preventive treatment plans to assist growth
9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN
- 9.1 INTRODUCTION
- 9.2 CURATIVE CARE
- 9.2.1 RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH
- 9.3 IMMUNIZATION
- 9.3.1 GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET
- 9.4 OTHER USAGE PATTERNS
10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION
- 10.1 INTRODUCTION
- 10.2 DERMAL-BASED ADMINISTRATION
- 10.2.1 RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH
- 10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
- 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH
- 10.4 ORGAN-BASED ADMINISTRATION
- 10.4.1 GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET
- 10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
- 10.5.1 INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH
11 INJECTABLE DRUG DELIVERY MARKET, BY END USER
- 11.1 INTRODUCTION
- 11.2 HOSPITALS & CLINICS
- 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
- 11.3 HOME CARE SETTINGS
- 11.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
- 11.4 LONG-TERM CARE SETTINGS
- 11.4.1 BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH
- 11.5 NURSING HOMES
- 11.5.1 GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH
- 11.6 OTHER END USERS
12 INJECTABLE DRUG DELIVERY MARKET, BY REGION
- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
- 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 12.2.2 US
- 12.2.2.1 Increasing prevalence of chronic diseases to expedite growth
- 12.2.3 CANADA
- 12.2.3.1 Growing preference for self-injection devices to drive market
- 12.3 EUROPE
- 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 12.3.2 GERMANY
- 12.3.2.1 High healthcare spending to propel growth
- 12.3.3 UK
- 12.3.3.1 Rising cases of obesity and diabetes to promote growth
- 12.3.4 FRANCE
- 12.3.4.1 Favorable health insurance system to accelerate growth
- 12.3.5 SPAIN
- 12.3.5.1 Favorable healthcare regulations support growth
- 12.3.6 ITALY
- 12.3.6.1 Regional variation in terms of coverage and benefits to hinder growth
- 12.3.7 NETHERLANDS
- 12.3.7.1 Growing focus on enhanced patient care to drive market
- 12.3.8 REST OF EUROPE
- 12.4 ASIA PACIFIC
- 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 12.4.2 CHINA
- 12.4.2.1 Large patient population and healthcare infrastructure improvements to augment growth
- 12.4.3 JAPAN
- 12.4.3.1 Supportive reimbursement policies and universal healthcare coverage to aid growth
- 12.4.4 INDIA
- 12.4.4.1 Rising diabetes and cardiovascular disease burden to propel market
- 12.4.5 AUSTRALIA
- 12.4.5.1 Increased patient volume to contribute to growth
- 12.4.6 SOUTH KOREA
- 12.4.6.1 Rising incidence of obesity and hypertension to amplify growth
- 12.4.7 THAILAND
- 12.4.7.1 Expanding self-administration options to support growth
- 12.4.8 VIETNAM
- 12.4.8.1 Rising investments and regulatory reforms to support market growth
- 12.4.9 REST OF ASIA PACIFIC
- 12.5 LATIN AMERICA
- 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 12.5.2 BRAZIL
- 12.5.2.1 Surge in obesity issues to stimulate growth
- 12.5.3 MEXICO
- 12.5.3.1 Increasing incidence of chronic diseases to drive market
- 12.5.4 REST OF LATIN AMERICA
- 12.6 MIDDLE EAST & AFRICA
- 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 12.6.2 GCC COUNTRIES
- 12.6.2.1 Saudi Arabia
- 12.6.2.1.1 Healthcare reforms to contribute to growth
- 12.6.2.2 United Arab Emirates (UAE)
- 12.6.2.2.1 Growing infrastructure investments to drive market
- 12.6.2.3 Rest of GCC Countries
- 12.6.3 REST OF MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
- 13.1 OVERVIEW
- 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 13.3 REVENUE ANALYSIS, 2020-2024
- 13.3.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
- 13.3.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
- 13.4 MARKET SHARE ANALYSIS, 2024
- 13.4.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
- 13.4.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
- 13.5 BRAND/PRODUCT COMPARISON
- 13.6 R&D EXPENDITURE OF KEY PLAYERS
- 13.7 COMPANY VALUATION AND FINANCIAL METRICS
- 13.7.1 COMPANY VALUATION
- 13.7.2 FINANCIAL METRICS
- 13.8 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- 13.8.1 STARS
- 13.8.2 EMERGING LEADERS
- 13.8.3 PERVASIVE PLAYERS
- 13.8.4 PARTICIPANTS
- 13.8.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024
- 13.8.5.1 Company footprint
- 13.8.5.2 Region footprint
- 13.8.5.3 Product type footprint
- 13.8.5.4 Usage pattern footprint
- 13.8.5.5 Therapeutic application footprint
- 13.8.5.6 Site of administration footprint
- 13.9 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
- 13.9.1 PROGRESSIVE COMPANIES
- 13.9.2 RESPONSIVE COMPANIES
- 13.9.3 DYNAMIC COMPANIES
- 13.9.4 STARTING BLOCKS
- 13.9.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
- 13.9.5.1 Detailed list of key startups/SMEs
- 13.9.5.2 Competitive benchmarking of startups/SMES
- 13.10 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- 13.10.1 STARS
- 13.10.2 EMERGING LEADERS
- 13.10.3 PERVASIVE PLAYERS
- 13.10.4 PARTICIPANTS
- 13.10.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024
- 13.10.5.1 Company footprint
- 13.10.5.2 Region footprint
- 13.10.5.3 Product type footprint
- 13.10.5.4 Formulation packaging type footprint
- 13.10.5.5 Therapeutic application footprint
- 13.10.5.6 Site of administration footprint
- 13.11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
- 13.11.1 PROGRESSIVE COMPANIES
- 13.11.2 RESPONSIVE COMPANIES
- 13.11.3 DYNAMIC COMPANIES
- 13.11.4 STARTING BLOCKS
- 13.11.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024
- 13.11.5.1 Detailed list of key startups/SMEs
- 13.11.5.2 Competitive benchmarking of startups/SMEs
- 13.12 COMPETITIVE SCENARIO
- 13.12.1 PRODUCT LAUNCHES AND APPROVALS
- 13.12.2 DEALS
- 13.12.3 EXPANSIONS
14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
- 14.1 KEY PLAYERS
- 14.1.1 CARDINAL HEALTH
- 14.1.1.1 Business overview
- 14.1.1.2 Products offered
- 14.1.1.3 Recent developments
- 14.1.1.4 MnM view
- 14.1.1.4.1 Right to win
- 14.1.1.4.2 Strategic choices
- 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 BD
- 14.1.2.1 Business overview
- 14.1.2.2 Products offered
- 14.1.2.3 Recent developments
- 14.1.2.3.1 Deals
- 14.1.2.3.2 Expansions
- 14.1.2.4 MnM view
- 14.1.2.4.1 Right to win
- 14.1.2.4.2 Strategic choices
- 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 B. BRAUN SE
- 14.1.3.1 Business overview
- 14.1.3.2 Products offered
- 14.1.3.3 MnM view
- 14.1.3.3.1 Right to win
- 14.1.3.3.2 Strategic choices
- 14.1.3.3.3 Weaknesses and competitive threats
- 14.1.4 BAXTER
- 14.1.4.1 Business overview
- 14.1.4.2 Products offered
- 14.1.4.3 Recent developments
- 14.1.4.3.1 Product launches and approvals
- 14.1.4.4 MnM view
- 14.1.4.4.1 Right to win
- 14.1.4.4.2 Strategic choices
- 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 TERUMO CORPORATION
- 14.1.5.1 Business overview
- 14.1.5.2 Products offered
- 14.1.5.3 Recent developments
- 14.1.5.3.1 Product launches and approvals
- 14.1.5.3.2 Expansions
- 14.1.5.4 MnM view
- 14.1.5.4.1 Right to win
- 14.1.5.4.2 Strategic choices
- 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 PHILLIPS-MEDSIZE CORPORATION (MOLEX)
- 14.1.6.1 Business overview
- 14.1.6.2 Products offered
- 14.1.6.3 Recent developments
- 14.1.6.3.1 Product launches and approvals
- 14.1.6.3.2 Deals
- 14.1.6.3.3 Expansions
- 14.1.7 NIPRO
- 14.1.7.1 Business overview
- 14.1.7.2 Products offered
- 14.1.7.3 Recent developments
- 14.1.8 ICU MEDICAL, INC.
- 14.1.8.1 Business overview
- 14.1.8.2 Products offered
- 14.1.8.3 Recent developments
- 14.1.9 WEST PHARMACEUTICAL SERVICES, INC.
- 14.1.9.1 Business overview
- 14.1.9.2 Products offered
- 14.1.9.3 Recent developments
- 14.1.9.3.1 Deals
- 14.1.9.3.2 Expansions
- 14.1.10 GERRESHEIMER AG
- 14.1.10.1 Business overview
- 14.1.10.2 Products offered
- 14.1.10.3 Recent developments
- 14.1.10.3.1 Product launches and approvals
- 14.1.10.3.2 Deals
- 14.1.10.3.3 Expansions
- 14.1.11 STEVANATO
- 14.1.11.1 Business overview
- 14.1.11.2 Products offered
- 14.1.11.3 Recent developments
- 14.1.11.3.1 Product launches and approvals
- 14.1.11.3.2 Deals
- 14.1.11.3.3 Expansions
- 14.1.12 SCHOTT PHARMA
- 14.1.12.1 Business overview
- 14.1.12.2 Products offered
- 14.1.12.3 Recent developments
- 14.1.12.3.1 Product launches and approvals
- 14.1.12.3.2 Deals
- 14.1.12.3.3 Expansions
- 14.1.13 MEDMIX
- 14.1.13.1 Business overview
- 14.1.13.2 Products offered
- 14.1.13.3 Recent developments
- 14.1.13.3.1 Product launches and approvals
- 14.1.13.3.2 Deals
- 14.1.14 SOLM
- 14.1.14.1 Business overview
- 14.1.14.2 Products offered
- 14.1.15 YPSOMED
- 14.1.15.1 Business overview
- 14.1.15.2 Products offered
- 14.1.15.3 Recent developments
- 14.1.15.3.1 Deals
- 14.1.15.3.2 Expansions
- 14.2 OTHER PLAYERS
- 14.2.1 OWEN MUMFORD
- 14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
- 14.2.3 POLYMEDICURE
- 14.2.4 UNION MEDICO INC.
- 14.2.5 SHL MEDICAL
- 14.2.6 ELCAM MEDICAL
15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
- 15.1 KEY PLAYERS
- 15.1.1 JOHNSON & JOHNSON SERVICES, INC.
- 15.1.1.1 Business overview
- 15.1.1.2 Products offered
- 15.1.1.3 Recent developments
- 15.1.1.3.1 Product launches and approvals
- 15.1.1.3.2 Deals
- 15.1.1.4 MnM view
- 15.1.1.4.1 Right to win
- 15.1.1.4.2 Strategic choices
- 15.1.1.4.3 Weaknesses and competitive threats
- 15.1.2 F. HOFFMANN-LA ROCHE LTD
- 15.1.2.1 Business overview
- 15.1.2.2 Products offered
- 15.1.2.3 Recent developments
- 15.1.2.3.1 Product launches and approvals
- 15.1.2.4 MnM view
- 15.1.2.4.1 Right to win
- 15.1.2.4.2 Strategic choices
- 15.1.2.4.3 Weaknesses and competitive threats
- 15.1.3 PFIZER INC.
- 15.1.3.1 Business overview
- 15.1.3.2 Products offered
- 15.1.3.3 Recent developments
- 15.1.3.3.1 Product launches and approvals
- 15.1.3.3.2 Deals
- 15.1.3.4 MnM view
- 15.1.3.4.1 Right to win
- 15.1.3.4.2 Strategic choices
- 15.1.3.4.3 Weaknesses and competitive threats
- 15.1.4 MERCK & CO., INC.
- 15.1.4.1 Business overview
- 15.1.4.2 Products offered
- 15.1.4.3 Recent developments
- 15.1.4.3.1 Product launches and approvals
- 15.1.4.3.2 Deals
- 15.1.4.3.3 Expansions
- 15.1.4.4 MnM view
- 15.1.4.4.1 Right to win
- 15.1.4.4.2 Strategic choices
- 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 NOVARTIS AG
- 15.1.5.1 Business overview
- 15.1.5.2 Products offered
- 15.1.5.3 Recent developments
- 15.1.5.3.1 Product launches and approvals
- 15.1.5.3.2 Deals
- 15.1.5.3.3 Expansions
- 15.1.5.4 MnM view
- 15.1.5.4.1 Right to win
- 15.1.5.4.2 Strategic choices
- 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 BAYER AG
- 15.1.6.1 Business overview
- 15.1.6.2 Products offered
- 15.1.6.3 Recent developments
- 15.1.6.3.1 Product launches and approvals
- 15.1.6.3.2 Expansions
- 15.1.7 ASTRAZENECA
- 15.1.7.1 Business overview
- 15.1.7.2 Products offered
- 15.1.7.3 Recent developments
- 15.1.7.3.1 Product launches and approvals
- 15.1.7.3.2 Deals
- 15.1.7.3.3 Expansions
- 15.1.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
- 15.1.8.1 Business overview
- 15.1.8.2 Products offered
- 15.1.8.3 Recent developments
- 15.1.8.3.1 Product launches and approvals
- 15.1.8.3.2 Deals
- 15.1.8.3.3 Expansions
- 15.1.9 ELI LILLY AND COMPANY
- 15.1.9.1 Business overview
- 15.1.9.2 Products offered
- 15.1.9.3 Recent developments
- 15.1.9.3.1 Product launches and approvals
- 15.1.9.3.2 Expansions
- 15.1.10 AMGEN INC.
- 15.1.10.1 Business overview
- 15.1.10.2 Products offered
- 15.1.10.3 Recent developments
- 15.1.10.3.1 Product launches and approvals
- 15.1.10.3.2 Deals
- 15.1.10.3.3 Expansions
- 15.1.11 NOVO NORDISK A/S
- 15.1.11.1 Business overview
- 15.1.11.2 Products offered
- 15.1.11.3 Recent developments
- 15.1.11.3.1 Product launches and approvals
- 15.1.11.3.2 Deals
- 15.1.11.3.3 Expansions
- 15.1.12 REGENERON PHARMACEUTICALS INC.
- 15.1.12.1 Business overview
- 15.1.12.2 Products offered
- 15.1.12.2.1 Product launches and approvals
- 15.1.12.2.2 Deals
- 15.1.13 FRESENIUS KABI AG
- 15.1.13.1 Business overview
- 15.1.13.2 Products offered
- 15.1.13.3 Recent developments
- 15.1.13.3.1 Product launches and approvals
- 15.1.14 UCB S.A.
- 15.1.14.1 Business overview
- 15.1.14.2 Products offered
- 15.1.14.3 Recent developments
- 15.1.14.3.1 Product launches and approvals
- 15.1.15 BIO-THERA SOLUTIONS, LTD.
- 15.1.15.1 Business overview
- 15.1.15.2 Products offered
- 15.1.15.3 Recent developments
- 15.1.15.3.1 Product launches and approvals
- 15.2 OTHER PLAYERS
- 15.2.1 SAGENT
- 15.2.2 VALNEVA SE
- 15.2.3 XERIS PHARMACEUTICALS, INC.
- 15.2.4 PHARMAESSENTIA CORPORATION
- 15.2.5 HERON THERAPEUTICS, INC.
16 APPENDIX
- 16.1 DISCUSSION GUIDE
- 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 16.3 RELATED REPORTS
- 16.4 AUTHOR DETAILS
